This article has been updated from a previous version to add comments from Qiagen's Q1 earnings call.

NEW YORK (GenomeWeb) – Qiagen reported after the close of the market on Tuesday that its first quarter revenues rose 3 percent, bolstered by increases in sales from every business except instruments.

For the three months ended March 31, the company reported revenues of $307.7 million, up from $298.4 million a year ago, and beating the average Wall Street estimate of $306.9 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.